We aggregated coding variant data for 81,412 type 2 diabetes cases and 370,832 controls of diverse ancestry, identifying 40 coding variant association signals (P < 2.2 × 10 −7 ); of these, 16 map outside known risk-associated loci. We make two important observations. First, only five of these signals are driven by low-frequency variants: even for these, effect sizes are modest (odds ratio ≤ 1.29). Second, when we used large-scale genome-wide association data to fine-map the associated variants in their regional context, accounting for the global enrichment of complex trait associations in coding sequence, compelling evidence for coding variant causality was obtained for only 16 signals. At 13 others, the associated coding variants clearly represent 'false leads' with potential to generate erroneous mechanistic inference. Coding variant associations offer a direct route to biological insight for complex diseases and identification of validated therapeutic targets; however, appropriate mechanistic inference requires careful specification of their causal contribution to disease predisposition.
G
enome-wide association studies (GWAS) have identified thousands of association signals influencing multifactorial traits such as type 2 diabetes (T2D) and obesity [1] [2] [3] [4] [5] [6] [7] . Most of these associations involve common variants that map to noncoding sequence, and identification of their cognate effector transcripts has proved challenging. Identification of coding variants causally implicated in trait predisposition offers a more direct route from association signal to biological inference.
The exome occupies 1.5% of the overall genome sequence, but, for many common diseases, coding variants make a disproportionate contribution to trait heritability 8, 9 . This enrichment indicates that coding variant association signals have an enhanced probability of being causal when compared to signals involving an otherwise equivalent noncoding variant. This does not, however, guarantee that all coding variant associations are causal. Alleles driving common variant (minor allele frequency (MAF) ≥ 5%) GWAS signals typically reside on extended risk haplotypes that, owing to linkage disequilibrium (LD), incorporate many common variants 10, 11 . Consequently, the presence of a coding allele on the risk haplotype does not constitute sufficient evidence that it represents the causal variant at the locus or that the gene within which it lies is mediating the association signal. Because much coding variant discovery has proceeded through exome-specific analyses (either exome array genotyping or exome sequencing), researchers have often been poorly placed to position coding variant associations in the context of regional genetic variation. It is unclear how often this may have led to incorrect assumptions regarding the causal role of coding variants.
In our recent study of T2D predisposition 12 , we surveyed the exomes of 34,809 cases and 57,985 controls, of predominantly European descent, and identified 13 distinct coding variant associations reaching genome-wide significance. Twelve of these associations involved common variants, but the data hinted at a substantial pool of lower-frequency coding variants of moderate impact, potentially amenable to detection in larger samples. We also reported that, while many of these signals fell within common variant loci previously identified by GWAS, it was far from trivial to determine, using available data, whether those coding variants were causal or 'hitchhiking' on risk haplotypes.
Here we report analyses that address these two issues. First, we extended the scope of our exome array genotyping to include data from 81,412 T2D cases and 370,832 controls of diverse ancestry, substantially increasing power to detect coding variant associations across the allele frequency spectrum. Second, to understand the extent to which identification of coding variant associations provides a reliable guide to causal mechanisms, we undertook high-resolution fine-mapping of identified coding variant association signals in 50,160 T2D cases and 465,272 controls of European ancestry with genome-wide genotyping data.
Results
Discovery study overview. First, we set out to discover coding variant association signals by aggregating T2D association summary statistics in up to 452,244 individuals (effective sample size of 228,825) across five ancestry groups, performing both European-specific (EUR) and trans-ethnic (TE) meta-analyses (Supplementary Tables 1  and 2 ). Analysis was restricted to the 247,470 variants represented on the exome array. Genotypes were assembled from (i) 58,425 cases and 188,032 controls genotyped with the exome array; (ii) 14,608 cases and 174,322 controls from UK Biobank and GERA (Resource for Genetic Epidemiology on Adult Health and Aging) genotyped with GWAS arrays enriched for exome content and/or coverage of low-frequency variation across ancestry groups 13, 14 ; and (iii) 8,379 cases and 8,478 controls with whole-exome sequence from the GoT2D/T2D-GENES 12 and SIGMA 15 studies. Overall, this represented a threefold increase in effective sample size over our previous study of T2D predisposition within coding sequence 12 . To deconvolute the impact of obesity on T2D-associated variants, association analyses were conducted with and without adjustment for body mass index (BMI).
We considered P < 2.2 × 10 −7 as significant for protein-truncating variants (PTVs) and moderate-impact coding variants (including missense, in-frame indel, and splice-region variants) on the basis of a weighted Bonferroni correction that accounts for the observed enrichment in complex trait association signals across sequence annotation 16 . This threshold matches those obtained through other approaches such as simple Bonferroni correction for the number of coding variants on the exome array (Methods). In comparison to our , the expanded sample size substantially increased power to detect association for common variants of modest effect (for example, power was increased from 14.4% to 97.9% for a variant with 20% MAF and odds ratio (OR) = 1.05) and lower-frequency variants with larger effects (for example, power was increased from 11.8% to 97.5% for a variant with 1% MAF and OR = 1.20) assuming homogenous allelic effects across ancestry groups (Methods).
Insights into coding variant association signals underlying T2D susceptibility. We detected significant associations at 69 coding variants under an additive genetic model (either in BMI-unadjusted or BMI-adjusted analysis), mapping to 38 loci (Supplementary Fig. 1 and Supplementary Table 3) . We observed minimal evidence of heterogeneity in allelic OR between ancestry groups (Supplementary Table 3 ) and no compelling evidence for nonadditive allelic effects (Supplementary Fig. 2 and Supplementary Table 4 ). Reciprocal conditional analyses (Methods) indicated that the 69 coding variants represented 40 distinct association signals (conditional P < 2.2 × 10 −7
) across the 38 loci, with 2 distinct signals each at HNF1A and RREB1 (Supplementary Table 5 ). These 40 signals included the 13 associations reported in our earlier publication 12 , each featuring more significant associations in this expanded meta-analysis (Supplementary Table 6 ). Twenty-five of the 40 signals were significant in both EUR and TE analyses. Of the other 15, 3 (PLCB3, C17orf58, and ZHX3) were significant in EUR analysis and all reached P TE < 6.8 × 10 −6 in the TE analysis: for PLCB3 and ZHX3, risk allele frequencies were substantially lower outside Europeandescent populations. Twelve loci (Supplementary Table 3) were significant in TE analysis alone, but for these (except PAX4, which is specific to East Asians) the evidence for association was proportionate in the smaller EUR component (P EUR < 8.4 × 10
−5
). Sixteen of the 40 distinct association signals mapped outside regions previously implicated in T2D susceptibility (Table 1 and Methods). These included missense variant signals in POC5 (p.His36Arg, rs2307111, P TE = 1.6 × 10
−15
), PNPLA3 (p.Ile148Met, rs738409, P TE BMI adjusted = 2.8 × 10
−11
), and ZZEF1 (p.Ile2014Val, rs781831, P TE = 8.3 × 10
). In addition to the 69 coding variant signals, we detected significant (P < 5 × 10 −8
) and new T2D associations for 20 noncoding variants (at 15 loci) that were also assayed on the exome array (Supplementary Table 7 ). Three of these (POC5, LPL, and BPTF) overlapped with new coding signals reported here.
Contribution of low-frequency and rare coding variation to T2D susceptibility. Despite increased power and good coverage of low-frequency variants on the exome array 12 , 35 of the 40 distinct coding variant association signals were common, with modest effects (allelic ORs of 1.02-1.36) ( Supplementary Fig. 3 and Supplementary Table 3) . The five signals attributable to lower-frequency variants were also of modest effect (allelic ORs of 1.09-1.29) (Supplementary Fig. 3) . Two of the lower-frequency variant signals were new, and, for both, the minor allele was protective against T2D: FAM63A p.Tyr95Asn (rs140386498, MAF = 1.2%, OR = 0.82 (0.77-0.88, 95% confidence interval), P EUR = 5.8 × 10 ) and ANKH p.Arg187Gln (rs146886108, MAF = 0.4%, OR = 0.78 (0.69-0.87), P EUR = 2.0 × 10
−7
). Both variants were very rare or monomorphic in individuals not of European descent.
In our previous study 12 , we highlighted a set of 100 low-frequency coding variants with allelic ORs between 1.10 and 2.66 that, despite relatively large estimates for liability-scale variance explained, had not reached significance. In this expanded analysis, only five of these variants, including two new associations (at FAM63A p.Tyr95Asn and ANKH p.Arg187Gln), attained significance. More precise effect size estimation in the larger sample size indicates that OR estimates in the earlier study were subject to a substantial upward bias (Supplementary Fig. 3 ).
To detect additional rare variant association signals, we performed gene-based analyses (burden and SKAT 17 ) using previously defined 'strict' and 'broad' masks, filtered for annotation and MAF 12, 18 (Methods). We identified gene-based associations with T2D susceptibility (P < 2.5 × 10 , Bonferroni correction for 20,000 genes) for FAM63A (10 variants, combined MAF = 1.9%, P EUR = 3.1 × 10 −9
) and PAM (17 variants, combined MAF = 4.7%, P TE = 8.2 × 10
−9
). On conditional analysis (Supplementary Table 8 ), the gene-based signal at FAM63A was entirely attributable to the low-frequency allele encoding p.Tyr95Asn described earlier (conditional P EUR = 0.26). The gene-based signal for PAM was also driven by a single low-frequency variant (p.Asp563Gly; conditional P TE = 0.15). A second previously described, low-frequency variant (PAM p.Ser539Trp 19 ) is not represented on the exome array and did not contribute to these analyses.
Fine-mapping of coding variant association signals with T2D susceptibility. These analyses identified 40 distinct coding variant associations with T2D, but this information is not sufficient to determine that these variants are causal for disease. To assess the role of these coding variants given regional genetic variation, we finemapped these association signals using a meta-analysis of 50,160 T2D cases and 465,272 controls (European descent only; partially overlapping with the discovery samples), which we aggregated from 24 GWAS. Each component GWAS was imputed using appropriate high-density reference panels (for most, the Haplotype Reference Consortium 20 ; Methods and Supplementary Table 9 ). Before finemapping, distinct association signals were delineated using approximate conditional analyses (Methods and Supplementary Table 5 ). We included 37 of the 40 identified coding variants in this fine-mapping analysis, excluding 3 (those in the major histocompatibility complex (MHC) region, PAX4, and ZHX3) that were, for various reasons (see the Methods), not amenable to fine-mapping in the GWAS data.
For each of these 37 signals, we first constructed 'functionally unweighted' credible variant sets, which collectively account for 99% of the posterior probability of association (PPA), based exclusively on the meta-analysis summary statistics 21 (Methods and Supplementary  Table 10) . For each signal, we calculated the proportion of PPA attributable to coding variants (missense, in-frame indel, and splice-region variants; Fig. 1 and Supplementary Figs. 4 and 5 ). There were only two signals at which coding variants accounted for ≥ 80% of PPA: HNF4A p.Thr139Ile (rs1800961, PPA > 0.999) and RREB1 p.Asp1171Asn (rs9379084, PPA = 0.920). However, at other signals, including those for GCKR p.Pro446Leu and SLC30A8 p.Arg276Trp, for which robust empirical evidence has established a causal role 22, 23 , genetic support for coding variant causation was weak. This is because coding variants were typically in high LD (r 2 > 0.9) with large numbers of noncoding variants, such that the PPA was distributed across many sites with broadly equivalent evidence for association.
These functionally unweighted sets are based on genetic fine-mapping data alone and do not account for the disproportionate representation of coding variants among GWAS associations for complex traits 8, 9 . To accommodate this information, we extended the fine-mapping analyses by incorporating an 'annotation-informed prior' model of causality. We derived priors from estimates of the enrichment of association signals by sequence annotation from analyses conducted by deCODE across 96 quantitative and 123 binary phenotypes 16 (Methods). This model 'boosts' the prior and, hence, the posterior probabilities (we use ' ai PPAs' to denote annotation-informed PPAs) of coding variants. It also takes into account (in a tissue-non-specific manner) the GWAS enrichment of variants within enhancer elements (as assayed through DNase I hypersensitivity) when compared to noncoding variants mapping elsewhere. The annotation-informed model generated smaller 99% credible sets across most signals, corresponding to fine-mapping at higher resolution (Supplementary Table 10 ). As expected, the contribution of coding variants was increased under Fine-mapping of 37 distinct association signals was performed using European-ancestry GWAS meta-analysis including 50,160 T2D cases and 465,272 controls. For each signal, we constructed a credible set of variants accounting for 99% of the posterior probability of driving the association, incorporating an annotation-informed prior model of causality, which boosts the posterior probability of driving the association signal that is attributed to coding variants. Each bar represents a signal, with the total probability attributed to the coding variants within the 99% credible set plotted on the y axis. When the probability (bar) is split across multiple coding variants (at least 0.05 probability attributed to a variant) at a particular locus, these variants are indicated by blue, pink, yellow, and green. The combined probability of the remaining coding variants is highlighted in gray. (Table 2) . At several of these, independent evidence corroborates the causal role of the genes harboring the associated coding variants. For example, rare coding mutations at HNF1A and HNF4A are causal for monogenic, early-onset forms of diabetes 24 , and at TM6SF2 and PNPLA3 the associated coding variants are implicated in the development of non-alcoholic fatty liver disease (NAFLD) 25, 26 . The use of priors to capture the enrichment of coding variants seems a reasonable model, across the genome. However, at any given locus, strong priors (especially for PTVs) might elevate to apparent causality variants that would have been excluded from a causal role on the basis of genetic fine-mapping alone. Comparison of the annotation-informed and functionally unweighted credible sets for group 1 signals indicated that this scenario was unlikely. For 11 of the 16 (GCKR, PAM, KCNJ11-ABCC8, HNF4A, RREB1 (p.Asp1171Asn), ANKH, POC5, TM6SF2, HNF1A (p.Ala146Val), PLCB3, and PNPLA3), the coding variant had the highest PPA in the fine-mapping analysis (Table 2) , even under the functionally unweighted model. At SLC30A8, WSCD2, and GIPR, the coding variants had similar PPAs to the lead noncoding SNPs under the functionally unweighted prior (Table 2) . At these 14 signals, therefore, coding variants have either greater or equivalent PPA to the best flanking noncoding SNPs under the functionally unweighted model, but receive a boost in PPA after incorporating the annotation weights.
The situation is less clear at LPL. Here fine-mapping resolution is poor under the functionally unweighted prior and the coding variant sits on an extended haplotype in strong LD with noncoding variants, some with higher PPA, such as rs74855321 (PPA = 0.048) (compared to LPL p.Ser474* (rs328, PPA = 0.023)). However, LPL p.Ser474* is annotated as a PTV and benefits from a substantially increased prior that boosts its annotation-informed ranking (Table 2) . Ultimately, decisions regarding the causal role of any such variant must rest on the amalgamation of evidence from diverse sources, including detailed functional evaluation of the coding variants and of other variants with which they are in LD.
Group 2: T2D association signals not attributable to coding variants.
At 13 of the 37 distinct signals, coding variation accounted for < 20% of the PPA, even after applying the annotation-informed prior model. These signals are likely to be driven by local noncoding variation and mediated through regulatory mechanisms. Five of these signals (TPCN2, MLX, ZZEF1, C17orf58, and CEP68) represent new T2D association signals identified in the exome-focused analysis. Given the exome array discoveries, it would have been natural to consider the named genes at these and other loci in this group as candidates for mediation of their respective association signals. However, the fine-mapping analyses indicate that these coding variants do not provide useful mechanistic inference given low ai PPA ( Fig. 1 and Table 2 ).
The coding variant association at the CENTD2 (ARAP1) locus is a case in point. The association with the p.Gln802Glu variant in ARAP1 (rs56200889, P TE = 4.8 × 10 −8 but ai PPA < 0.001) is seen in the fine-mapping analysis to be secondary to a substantially stronger noncoding association signal involving a cluster of variants including rs11603334 (P TE = 9.5 × 10 −18
, ai PPA = 0.0692) and rs1552224 (P TE = 2.5 × 10 −17
, ai PPA = 0.0941). The identity of the effector transcript at this locus has been the subject of detailed investigation, and some early studies used islet expression data to promote ARAP1 27 . However, a more recent study integrating human islet genomics and mouse gene knockout data has established STARD10 as the gene mediating the GWAS signal, consistent with the reassignment of the ARAP1 coding variant association as irrelevant to causal inference 28 . While at these loci the coding variant associations represent false leads, this does not necessarily exclude the genes concerned from a causal role. At WFS1, for example, coding variants too rare to be visible to the array-based analyses we performed, and statistically ) (continued) independent of the common p.Val333Ile variant we detected, cause an early-onset form of diabetes that renders WFS1 the strongest local candidate for T2D predisposition.
Group 3: Fine-mapping data consistent with a partial role for coding variants. At 8 of the 37 distinct signals, the ai PPA attributable to coding variation lay between 20% and 80%. At these signals, the evidence is consistent with 'partial' contributions from coding variants, although the precise inference is likely to be locus specific, dependent on subtle variations in LD, imputation accuracy, and the extent to which global priors accurately represent the functional impact of the specific variants concerned. This group includes PPARG, for which independent evidence corroborates the causal role of this specific effector transcript with respect to T2D risk. PPARG encodes the target of antidiabetic thiazolidinedione drugs and harbors very rare coding variants causal for lipodystrophy and insulin resistance, conditions highly relevant to T2D. The common variant association signal at this locus has generally been attributed to the p.Pro12Ala coding variant (rs1801282), although empirical evidence that this variant influences PPARγ function is scant [29] [30] [31] . In the functionally unweighted analysis, p.Pro12Ala had an unimpressive PPA (0.0238); after including annotation-informed priors, the same variant emerged with the highest ai PPA (0.410), although the 99% credible set included 19 noncoding variants, spanning 67 kb (Supplementary Table 10 ). These credible set variants included rs4684847 ( ai PPA = 0.0089), at which the T2D-associated allele has been reported to impact PPARG expression and insulin sensitivity by altering binding of the homeobox transcription factor PRRX1 32 . These data are consistent with a model whereby regulatory variants contribute to altered PPARγ activity in combination with, or potentially to the exclusion of, p.Pro12Ala. Future improvements in functional annotation for regulatory variants (gathered from relevant tissues and cell types) should provide increasingly granular priors that allow fine-tuned assignment of causality at loci such as this.
Functional impact of coding alleles. In other contexts, the functional impact of coding alleles is correlated with (i) variant-specific features, including measures of conservation and predicted impact on protein structure, and (ii) gene-specific features, such as extreme selective constraints as quantified by the intolerance to functional variation 33 . To determine whether similar measures could capture information pertinent to T2D causation, we compared coding variants falling into the different fine-mapping groups for a variety of measures, including MAF, Combined AnnotationDependent Depletion (CADD) score 34 , and the loss-of-function (LoF) intolerance metric pLI 33 ( Fig. 2 and Methods). Variants from group 1 had significantly higher CADD scores than those in group 2 (Kolmogorov-Smirnov P = 0.0031). Except for the variants at KCNJ11-ABCC8 and GCKR, all group 1 coding variants considered likely to be driving T2D association signals had a CADD score ≥ 20. On this basis, we predict that the East Asian-specific coding variant at PAX4, for which the fine-mapping data were not informative, is also likely causal for T2D.
T2D loci and physiological classification. The development of T2D involves dysfunction of multiple mechanisms. Systematic analysis of the physiological effects of known T2D risk alleles has improved understanding of the mechanisms through which these alleles exert their primary impact on disease risk 35 . We obtained association summary statistics for diverse metabolic traits , and the color represents the fine-mapping group to which each variant is assigned. In group 1, signal is driven by the coding variant; in group 2, signal is attributable to noncoding variants; in group 3, signal is consistent with a partial role for coding variants. Group 4 represents an unclassified category and includes PAX4, ZHX3, and signal at TCF19 within the MHC region where we did not perform finemapping. Inset, plot showing the distribution of CADD scores between different groups. The plot is a combination of violin plots and box plots; the width of each violin corresponds to the frequency at the corresponding CADD score, and box plots show the median and the 25% and 75% quantiles. The P value indicates significance from a two-sample Kolmogorov-Smirnov test. Fig. 6 and Supplementary Table 11 ). The first category, comprising nine T2D risk loci with strong BMI and dyslipidemia associations, included three of the new coding signals: PNPLA3, POC5, and BPTF. The T2D associations at both POC5 and BPTF were substantially attenuated (> 2-fold decrease in -log 10 P) after adjusting for BMI (Table 1 , Supplementary Fig. 7 , and Supplementary Table 3 ), indicating that their impact on T2D risk is likely mediated by a primary effect on adiposity. PNPLA3 and POC5 are established loci for NAFLD 25 and BMI 6 , respectively. The second category featured 39 loci at which multi-trait profiles indicated a primary effect on insulin secretion. This set included four of the new coding variant signals (ANKH, ZZEF1, TTLL6, and ZHX3). The third category encompassed 23 loci with primary effects on insulin action, including signals at the KIF9, PLCB3, CEP68, TPCN2, FAM63A, and PIM3 loci. For most variants in this category, the T2D risk allele was associated with lower BMI, and T2D association signals were more pronounced after adjustment for BMI. At a subset of these loci, including KIF9 and PLCB3, the T2D risk alleles were associated with higher waist-hip ratio and lower body fat percentage, indicating that the mechanism of action likely reflects limitations in storage capacity of peripheral adipose tissue 36 .
Discussion
The present study adds to mounting evidence constraining the contribution of lower-frequency variants to T2D risk. Although the exome array interrogates only a subset of the universe of coding variants, it captures the majority of low-frequency coding variants in European populations. The substantial increase in sample size in the present study over our previous effort 12 (effective sample sizes of 228,825 and 82,758, respectively) provides more robust evaluation of the effect size distribution in this low-frequency variant range and indicates that previous analyses are likely, if anything, to have overestimated the contribution of low-frequency variants to T2D risk.
The present study is less informative regarding rare variants. These are sparsely captured on the exome array. In addition, the combination of greater regional diversity in rare allele distribution and the enormous sample sizes necessary to detect rare variant associations (likely to require meta-analysis of data from diverse populations) acts against their identification. Our complementary genome and exome sequence analyses have thus far failed to register strong evidence for a substantial rare variant component to T2D risk 12 . It is therefore highly unlikely that rare variants missed in our analyses are causal for any of the common or low-frequency variant associations we have detected and fine-mapped. On the other hand, it is probable that rare coding alleles, with associations that are distinct from the common variant signals we have examined and detected only through sequence-based analyses, will provide additional clues to the most likely effector transcripts at some of these signals (WFS1 provides one such example).
Once a coding variant association is detected, it is natural to assume a causal connection between that variant, the gene in which it sits, and the phenotype of interest. While such assignments may be robust for many rare protein-truncating alleles, we demonstrate that this implicit assumption is often inaccurate, particularly for associations attributable to common, missense variants. One-third of the coding variant associations we detected were, when assessed in the context of regional LD, highly unlikely to be causal. At these loci, the genes within which they reside are consequently deprived of their implied connection to disease risk and attention is redirected toward nearby noncoding variants and their impact on regional gene expression. As a group, coding variants we assign as causal are predicted to have a more deleterious impact on gene function than those that we exonerate, but, as in other settings, coding annotation methods lack both sensitivity and specificity. It is worth emphasizing that empirical evidence that the associated coding allele is 'functional' (that is, can be shown to influence cognate gene function in some experimental assay) provides limited reassurance that the coding variant is responsible for the T2D association, unless that specific perturbation of gene function can itself be plausibly linked to the disease phenotype.
Our fine-mapping analyses make use of the observation that coding variants are globally enriched across GWAS signals 8, 9, 16 , with greater prior probability of causality assigned to those with more severe impact on biological function. We assigned diminished priors to noncoding variants, with the lowest support for those mapping outside of DNase I-hypersensitive sites. The extent to which our findings corroborate previous assignments of causality (often substantiated by detailed, disease-appropriate functional assessment and other orthogonal evidence) suggests that even these sparse annotations provide valuable information to guide target validation. Nevertheless, there are inevitable limits to the extrapolation of these 'broad-brush' genome-wide enrichments to individual loci: improvements in functional annotation for both coding and regulatory variants, particularly when gathered from trait-relevant tissues and cell types, should provide more granular, trait-specific priors to fine-tune assignment of causality within associated regions. These will motivate target validation efforts that benefit from the synthesis of both coding and regulatory mechanisms of gene perturbation. It also needs to be acknowledged that, without wholegenome sequencing data on sample sizes comparable to those we have examined here, imperfections arising from the imputation may confound fine-mapping precision at some loci and that robust inference will inevitably depend on integration of diverse sources of genetic, genomic, and functional data. The term 'smoking gun' has often been used to describe the potential of functional coding variants to provide causal inference with respect to pathogenetic mechanisms 37 . This study provides a timely reminder that, even when a suspect with a smoking gun is found at the scene of a crime, it should not be assumed that they fired the fatal bullet.
URLs. Type 2 Diabetes Knowledge Portal, http://www.type2diabe-tesgenetics.org/.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0084-1. Derivation of significance thresholds. We considered five categories of annotation 16 of variants on the exome array in order of decreasing effect on biological function: (i) PTVs (stop-gain and stop-loss, frameshift indel, donor and acceptor splice-site, and initiator codon variants, n 1 = 8,388); (ii) moderate-impact variants (missense, in-frame indel, and splice-region variants, n 2 = 216,114); (iii) low-impact variants (synonymous, 3′ and 5′ UTR, and upstream and downstream variants, n 3 = 8,829); (iv) other variants mapping to DNase I-hypersensitive sites (DHSs) in any of 217 cell types 8 (DHSs, n 4 = 3,561); and (v) other variants not mapping to DHSs (n 5 = 10,578). To account for the greater prior probability of causality for variants with greater effect on biological function, we determined a weighted Bonferroni-corrected significance threshold on the basis of reported enrichment 16 , denoted w i , in each annotation category i: w 1 = 165; w 2 = 33; w 3 = 3; w 4 = 1. We note that this threshold is similar to a simple Bonferroni correction for the total number of coding variants on the array, which would yield Discovery exome array study-level analyses. Within each study, genotype calling and quality control were undertaken according to protocols developed by the UK Exome Chip Consortium or the CHARGE central calling effort 38 (Supplementary Table 1 ). Within each study, variants were then excluded for the following reasons: (i) not mapping to autosomes or the X chromosome; (ii) multiallelic and/or insertion-deletion; (iii) monomorphic; (iv) call rate < 99%; or (v) exact P < 10 −4 for deviation from Hardy-Weinberg equilibrium (autosomes only).
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We tested association of T2D with each variant in a linear mixed model, implemented in RareMetalWorker 17 , using a genetic relationship matrix (GRM) to account for population structure and relatedness. For participants from family-based studies, known relationships were incorporated directly in the GRM. For founders and participants from population-based studies, the GRM was constructed from pairwise identity-by-descent (IBD) estimates based on LD-pruned (r 2 < 0.05) autosomal variants with MAF ≥ 1% (across cases and controls combined), after exclusion of those in high LD and complex regions 39, 40 and those mapping to established T2D loci. We considered additive, dominant, and recessive models for the effect of the minor allele, adjusted for age and sex (where appropriate) and additional study-specific covariates (Supplementary Table 2 ). Analyses were also performed with and without adjustment for BMI (where available; Supplementary Table 2) .
For single-variant association analyses, variants with minor allele count ≤ 10 in cases and controls combined were excluded. Association summary statistics for each analysis were corrected for residual inflation by means of genomic control 41 , calculated after excluding variants mapping to established T2D susceptibility loci. For gene-based analyses, we made no variant exclusions on the basis of minor allele count.
Discovery exome sequence analyses. We used summary statistics of T2D association from analyses conducted on 8,321 T2D cases and 8,421 controls across different ancestries, all genotyped using exome sequencing. Details of samples included, sequencing, and quality control are described elsewhere 12, 15 (http://www. type2diabetesgenetics.org/). Samples were divided into 15 subgroups according to ancestry and study of origin. Each subgroup was analyzed independently, with subgroup-specific principal components and GRMs. Association tests were performed with both a linear mixed model, as implemented in EMMAX 42 , using covariates for sequencing batch, and the Firth test, using covariates for principal components and sequencing batch. Related samples were excluded from the Firth analysis but maintained in the linear mixed model analysis. Variants were then filtered from each subgroup analysis, according to call rate, differential casecontrol missingness, or deviation from Hardy-Weinberg equilibrium (as computed separately for each subgroup). Association statistics were then combined via a fixed-effects inverse-variance-weighted meta-analysis, both at the level of ancestry and across all samples. P values were taken from the linear mixed model analysis, while effect size estimates were taken from the Firth analysis. Analyses were performed with and without adjustment for BMI. From exome sequence summary statistics, we extracted variants passing quality control and present on the exome array.
Discovery GWAS analyses.
The UK Biobank is a large detailed prospective study of more than 500,000 participants aged 40-69 years when recruited in 2006-2010 13 . Prevalent T2D status was defined using self-reported medical history and medication in UK Biobank participants 43 . Participants were genotyped with the UK Biobank Axiom Array or UK BiLEVE Axiom Array, and quality control and population structure analyses were performed centrally at UK Biobank. We defined a subset of samples of 'white European' ancestry (n = 120,286) as those who both self-identified as white British and were confirmed as ancestrally European descent from the first two axes of genetic variation from principal-components analysis. Imputation was also performed centrally at UK Biobank for the autosomes only, up to a merged reference panel from the 1000 Genomes Project (multi-ethnic, phase 3, October 2014 release) 44 and the UK10K Project . We used SNPTESTv2.5 45 to test for association of T2D with each SNP in a logistic regression framework under an additive model and after adjustment for age, sex, six axes of genetic variation, and genotyping array as covariates. Analyses were performed with and without adjustment for BMI, after removing related individuals.
GERA is a large multi-ethnic population-based cohort, created for investigating the genetic and environmental basis of age-related diseases (dbGaP phs000674.p1). T2D status is based on ICD-9 codes in linked electronic medical health records, with all other participants defined as controls. Participants were previously genotyped using one of four custom arrays, which were designed to maximize coverage of common and low-frequency variants in non-Hispanic white, East Asian, African-American, and Latino ancestry groups 46, 47 . Methods for quality control have been described previously 14 . Each of the four genotyping arrays was imputed separately, up to the 1000 Genomes Project reference panel (autosomes, phase 3, October 2014 release; X chromosome, phase 1, March 2012 release) using IMPUTEv2.3 48, 49 . We used SNPTESTv2.5 45 to test for association of T2D with each SNP in a logistic regression framework under an additive model and after adjustment for sex and nine axes of genetic variation from principal-components analysis as covariates. BMI was not available for adjustment in GERA.
For UK Biobank and GERA, we extracted variants passing standard imputation quality-control thresholds (IMPUTE info ≥ 0.4) 50 and present on the exome array. Association summary statistics under an additive model were corrected for residual inflation by means of genomic control 41 , calculated after excluding variants mapping to established T2D susceptibility loci: GERA (λ = 1.097 for BMIunadjusted analysis) and UK Biobank (λ = 1.043 for BMI-unadjusted analysis, λ = 1.056 for BMI-adjusted analysis).
Discovery single-variant meta-analysis. We aggregated association summary statistics under an additive model across studies, with and without adjustment for BMI, using METAL 51 : (i) effective sample size weighting of z scores to obtain P values and (ii) inverse-variance weighting of log-odds ratios. For exome array studies, allelic effect sizes and standard errors obtained from the RareMetalWorker linear mixed model were converted to the log-odds scale before meta-analysis to correct for case-control imbalance 52 . The European-specific meta-analyses aggregated association summary statistics from a total of 48,286 cases and 250,671 controls from (i) 33 exome array studies of European ancestry; (ii) exome array sequence from individuals of European ancestry; and (iii) GWAS from UK Biobank. Note that noncoding variants represented on the exome array were not available in exome sequence. The European-specific meta-analyses were corrected for residual inflation by means of genomic control 41 , calculated after excluding variants mapping to established T2D susceptibility loci: λ = 1.091 for BMI-unadjusted analysis and λ = 1.080 for BMIadjusted analysis.
The trans-ethnic meta-analyses aggregated association summary statistics from a total of 81,412 cases and 370,832 controls across all studies (51 exome array studies, exome sequence, and GWAS from UK Biobank and GERA), irrespective of ancestry. Note that noncoding variants represented on the exome array were not available in exome sequence. The trans-ethnic meta-analyses were corrected for residual inflation by means of genomic control 41 , calculated after excluding variants mapping to established T2D susceptibility loci: λ = 1.073 for BMI-unadjusted analysis and λ = 1.068 for BMI-adjusted analysis. Heterogeneity in allelic effect sizes between exome array studies contributing to the trans-ethnic meta-analysis was assessed by Cochran's Q statistic 53 .
Discovery detection of distinct association signals.
Conditional analyses were undertaken to detect association signals by inclusion of index variants and/or tags for previously reported noncoding GWAS lead SNPs as covariates in the regression model at the study level. Within each exome array study, approximate conditional analyses were undertaken under a linear mixed model using RareMetal 17 , which uses score statistics and the variance-covariance matrix from the RareMetalWorker single-variant analysis to estimate the correlation in effect size estimates between variants due to LD. Study-level allelic effect sizes and standard errors obtained from the approximate conditional analyses were converted to the log-odds scale to correct for case-control imbalance 52 . Within each GWAS, exact conditional analyses were performed under a logistic regression model using SNPTESTv2.5 45 . GWAS variants passing standard imputation quality-control thresholds (IMPUTE info ≥ 0.4) 50 and present on the exome array were extracted for meta-analysis.
Association summary statistics were aggregated across studies, with and without adjustment for BMI, using METAL 51 : (i) effective sample size weighting of z scores to obtain P values and (ii) inverse-variance weighting of log-odds ratios.
We defined new loci as mapping > 500 kb from a previously reported lead GWAS SNP. We performed conditional analyses where a new signal mapped close to a known GWAS locus and the lead GWAS SNP at that locus was present (or tagged) on the exome array (Supplementary Table 5 ).
Discovery non-additive association models. For exome array studies only, we aggregated association summary statistics under recessive and dominant models across studies, with and without adjustment for BMI, using METAL 51 : (i) effective sample size weighting of z scores to obtain P values and (ii) inverse-variance weighting of log-odds ratios. Allelic effect sizes and standard errors obtained from the RareMetalWorker linear mixed model were converted to the log-odds scale before meta-analysis to correct for case-control imbalance 52 . The Europeanspecific meta-analyses aggregated association summary statistics from a total of 41,066 cases and 136,024 controls from 33 exome array studies of European ancestry. The European-specific meta-analyses were corrected for residual inflation by means of genomic control 41 , calculated after excluding variants mapping to established T2D susceptibility loci: λ = 1.076 and λ = 1.083 for BMI-unadjusted analysis, under the recessive and dominant models, respectively, and λ = 1.081 and λ = 1.062 for BMI-adjusted analysis, under the recessive and dominant models, respectively. The trans-ethnic meta-analyses aggregated association summary statistics from a total of 58,425 cases and 188,032 controls across all exome array studies, irrespective of ancestry. The trans-ethnic meta-analyses were corrected for residual inflation by means of genomic control 41 , calculated after excluding variants mapping to established T2D susceptibility loci: λ = 1.041 and λ = 1.071 for BMI-unadjusted analysis, under the recessive and dominant models, respectively, and λ = 1.031 and λ = 1.063 for BMI-adjusted analysis, under the recessive and dominant models, respectively.
Discovery gene-based meta-analyses. For exome array studies only, we aggregated association summary statistics under an additive model across studies, with and without adjustment for BMI, using RareMetal 17 . This approach uses score statistics and the variance-covariance matrix from the RareMetalWorker single-variant analysis to estimate the correlation in effect size estimates between variants due to LD. We performed gene-based analyses using a burden test (assuming all variants had the same direction of effect on T2D susceptibility) and SKAT (allowing variants to have different directions of effect on T2D susceptibility). We used two previously defined filters for annotation and MAF 18 to define group files: (i) a strict filter, including 44,666 variants, and (ii) a broad filter, including all variants from the strict filter and 97,187 additional variants.
We assessed the contribution of each variant to gene-based signals by performing approximate conditional analyses. We repeated RareMetal analyses for the gene, excluding each variant in turn from the group file, and compared the strengths of the association signal.
Fine-mapping of coding variant association signals with T2D susceptibility. We defined a locus as mapping 500 kb upstream and downstream of each index coding variant (Supplementary Table 5 ), excluding the MHC. Our fine-mapping analyses aggregated association summary statistics from 24 GWAS incorporating 50,160 T2D cases and 465,272 controls of European ancestry from the DIAGRAM Consortium (Supplementary Table 9 ). Each GWAS was imputed using miniMAC 12 or IMPUTEv2 48, 49 up to high-density reference panels: (i) 22 GWAS were imputed up to the Haplotype Reference Consortium 20 ; (ii) the UK Biobank GWAS was imputed to a merged reference panel from the 1000 Genomes Project (multiethnic, phase 3, October 2014 release) 44 and the UK10K Project ; and (iii) the deCODE GWAS was imputed up to the deCODE Icelandic population-specific reference panel based on whole-genome sequence data 19 . Association with T2D susceptibility was tested for each remaining variant using logistic regression, adjusting for age, sex, and study-specific covariates, under an additive genetic model. Analyses were performed with and without adjustment for BMI. For each study, variants with minor allele count < 5 (in cases and controls combined) or those with imputation quality r2-hat < 0.3 (miniMAC) or proper-info < 0.4 (IMPUTE2) were removed. Association summary statistics for each analysis were corrected for residual inflation by means of genomic control 41 , calculated after excluding variants mapping to established T2D susceptibility loci.
We aggregated association summary statistics across studies, with and without adjustment for BMI, in a fixed-effects inverse-variance-weighted meta-analysis, using METAL 51 . The BMI-unadjusted meta-analysis was corrected for residual inflation by means of genomic control (λ = 1.012) 41 , calculated after excluding variants mapping to established T2D susceptibility loci. No adjustment was required for BMI-adjusted meta-analysis (λ = 0.994). From the meta-analysis, variants were extracted that were present on the HRC panel and reported in at least 50% of the total effective sample size.
We included 37 of the 40 identified coding variants in fine-mapping analyses, excluding 3 that were not amenable to fine-mapping in the GWAS datasets: (i) the locus in the MHC region because of the extended and complex structure of LD across the region, which complicates fine-mapping efforts; (ii) the East Asianspecific PAX4 p.Arg190His (rs2233580) signal, as the variant was not present in European-ancestry GWAS; and (iii) ZHX3 p.Asn310Ser (rs4077129) because the variant was only weakly associated with T2D in the GWAS datasets used for finemapping.
To delineate distinct association signals in four regions, we undertook approximate conditional analyses, implemented in GCTA 54 , to adjust for the index coding variants and noncoding lead GWAS SNPs: (i) RREB1 p.Asp1171Asn (rs9379084), p.Ser1499Tyr (rs35742417), and rs9505118; (ii) HNF1A p.Ile75Leu (rs1169288) and p.Ala146Val (rs1800574); (iii) GIPR p.Glu318Gln (rs1800437) and rs8108269; and (iv) HNF4A p.Thr139Ile (rs1800961) and rs4812831. We made use of summary statistics from the fixed-effects meta-analyses (BMI unadjusted for RREB1, HNF1A, and HNF4A; BMI adjusted for GIPR, as this signal was only seen in BMI-adjusted analysis) and genotype data from 5,000 random individuals of European ancestry from the UK Biobank, as reference for LD between genetic variants across the region.
For each association signal, we first calculated an approximate Bayes' factor 55 in favor of association on the basis of allelic effect sizes and standard errors from the meta-analysis. Specifically, for the jth variant
where β j and V j denote the estimated allelic effect (log-OR) and corresponding variance from the meta-analysis. The parameter ω denotes the prior variance in allelic effects, taken here to be 0.04 55 . We then calculated the posterior probability that the jth variant drives the association signal, given by
In this expression, ρ j denotes the prior probability that the jth variant drives the association signal and the summation in the denominator is over all variants across the locus. We considered two prior models: (i) functionally unweighted, for which ρ j = 1 for all variants, and (ii) annotation informed, for which ρ j is determined by the functional severity of the variant. For the annotation-informed prior, we considered five categories of variation 16 , such that (i) ρ j = 165 for PTVs; (ii) ρ j = 33 for moderate-impact variants; (iii) ρ j = 3 for low-impact variants; (iv) ρ j = 1.5 for other variants mapping to DHSs; and (v) ρ j = 0.5 for all other variants.
For each locus, the 99% credible set 21 under each prior was then constructed by (i) ranking all variants according to their posterior probability of driving the association signal and (ii) including ranked variants until their cumulative posterior probability of driving the association equaled or exceeded 0.99.
Functional impact of coding alleles. We used CADD
34 to obtain scaled CADD scores for each of the 40 significantly associated coding variants. The CADD method objectively integrates a range of different annotation metrics into a single measure (CADD score), providing an estimate of deleteriousness for all known variants and an overall rank for this metric across the genome. We obtained estimates of the intolerance of a gene to harboring LoF variants (pLI) from the ExAC dataset 33 . We used the Kolmogorov-Smirnov test to determine whether fine-mapping groups 1 and 2 had the same statistical distribution for each of these parameters.
T2D loci and physiological classification.
To explore the different patterns of association between T2D and other anthropometric, metabolic, and/or endocrine traits and diseases, we performed hierarchical clustering analysis. We obtained association summary statistics for a range of metabolic traits and other outcomes for 94 coding and noncoding variants that were significantly associated with T2D through collaboration or by querying publically available GWAS meta-analysis datasets. The z score (allelic effect/standard error) was aligned to the T2D risk allele. We obtained the distance matrix among the z scores of the loci/traits using the Euclidean measure and performed clustering using the complete agglomeration method. Clustering was visualized by constructing a dendrogram and heat map. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
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